Monday, February 02, 2026
Motley Fool Money
Biotech's Mixed Signals: FDA Turbulence, GLP-1 Dominance, and DNA Innovation
Amidst biotech's recent strength, FDA approval volatility adds risk. Meanwhile, weight-loss drugs drive big pharma growth, and DNA synthesis firms show resilience.
Biotech Investing
FDA Regulation
Gene Therapy
Weight Loss Drugs
Pharmaceuticals
Earnings Report
DNA Synthesis
5 min read